Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II ...

Albany College of Pharmacy and Health Sciences’ Professor Tom Lodise will lead a study on complicated urinary tract infections (cUTI's) caused by enterobacterales, a type of bacteria.

Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration The 12-16-week open-label study evaluated Ruxoprubart as ...

Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II clinical trial (RCT), offering an early signal that could reshape how advanced ...

Therapeutic drug monitoring would seem like an obvious match with rheumatology. Patients with clinically challenging ...

Henry Ford Health has treated the first Michigan patient outside clinical trials with Roctavian, the newly approved gene ...

Our furry friends have curious natures, and even though we try our best to keep them safe and healthy, they may still get ...

Life-saving treatments for children with orphan illnesses often move slowly, if at all, through the federal approval process.

Severe cases may need oxygen, IV fluids or corticosteroids. Antibiotics don’t work since they are to combat bacteria, and ...

Declan O’Brien had a unique overview of one of the fastest-growing areas within medical therapy – intravenous foods and medicines for the treatment of complex diseases such as cancer. O’Brien was at ...

The global nasal drug delivery technology market is projected to grow at a CAGR of approximately 7% over the next five years.

The NHS is celebrating one year since patients first began receiving medicines made from UK plasma.